These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30728962)
1. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight Fox AN; Smith WJ; Kupiec KE; Harding SJ; Resman-Targoff BH; Neely SB; White BP; Owens RE Ther Adv Infect Dis; 2019; 6():2049936118820230. PubMed ID: 30728962 [TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Bookstaver PB; Bland CM; Qureshi ZP; Faulkner-Fennell CM; Sheldon MA; Caulder CR; Hartis C; Pharmacotherapy; 2013 Dec; 33(12):1322-30. PubMed ID: 23712701 [TBL] [Abstract][Full Text] [Related]
3. A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. Butterfield-Cowper JM; Lodise TP; Pai MP Pharmacotherapy; 2018 Sep; 38(9):981-985. PubMed ID: 29906315 [TBL] [Abstract][Full Text] [Related]
4. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. Vlashyn OO; Lorenz AM; Sobhanie MM; Smith JM; Bond M; Wardlow L J Clin Pharm Ther; 2021 Apr; 46(2):363-368. PubMed ID: 33016513 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Ng JK; Schulz LT; Rose WE; Fox BC; Andes DR; Buhr KA; Fish JT Antimicrob Agents Chemother; 2014; 58(1):88-93. PubMed ID: 24145531 [TBL] [Abstract][Full Text] [Related]
6. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Tsu LV; Dager WE Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825 [TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Britt NS; Potter EM; Patel N; Steed ME Clin Infect Dis; 2017 Mar; 64(5):605-613. PubMed ID: 28011602 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of obesity on voriconazole serum concentrations. Koselke E; Kraft S; Smith J; Nagel J J Antimicrob Chemother; 2012 Dec; 67(12):2957-62. PubMed ID: 22915462 [TBL] [Abstract][Full Text] [Related]
10. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. Ando M; Nishioka H; Nakasako S; Kuramoto E; Ikemura M; Kamei H; Sono Y; Sugioka N; Fukushima S; Hashida T J Clin Pharm Ther; 2020 Apr; 45(2):290-297. PubMed ID: 31696963 [TBL] [Abstract][Full Text] [Related]
11. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Natale S; Bradley J; Nguyen WH; Tran T; Ny P; La K; Vivian E; Le J Pharmacotherapy; 2017 Mar; 37(3):361-378. PubMed ID: 28079262 [TBL] [Abstract][Full Text] [Related]
12. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. Polso AK; Lassiter JL; Nagel JL J Clin Pharm Ther; 2014 Dec; 39(6):584-608. PubMed ID: 25203631 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Total Body Weight versus Adjusted Body Weight Liposomal Amphotericin B Dosing in Obese Patients. Ting MH; Spec A; Micek ST; Ritchie DJ; Krekel T Antimicrob Agents Chemother; 2021 Aug; 65(9):e0236620. PubMed ID: 34125591 [TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172 [TBL] [Abstract][Full Text] [Related]
15. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Pai MP; Norenberg JP; Anderson T; Goade DW; Rodvold KA; Telepak RA; Mercier RC Antimicrob Agents Chemother; 2007 Aug; 51(8):2741-7. PubMed ID: 17548489 [TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category. Zhang MM; Stevens RW; Adema JL; Mara KC; Schuetz AN; Tande AJ; Rivera CG Infect Dis Ther; 2023 Sep; 12(9):2295-2305. PubMed ID: 37751018 [TBL] [Abstract][Full Text] [Related]
17. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. McConnell HL; Perris ET; Lowry C; Lodise T; Patel N Infect Dis Ther; 2014 Dec; 3(2):225-33. PubMed ID: 25245515 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a daptomycin dose-optimization protocol. Tran TT; Palmer HR; Weston J; Hirsch EB; Shah DN; Cottreau J; Tam VH; Garey KW Am J Health Syst Pharm; 2012 Jun; 69(11):979-84. PubMed ID: 22610031 [TBL] [Abstract][Full Text] [Related]
19. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. Kullar R; Casapao AM; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ J Antimicrob Chemother; 2013 Dec; 68(12):2921-6. PubMed ID: 23928022 [TBL] [Abstract][Full Text] [Related]